Biotechnology and diagnostic company Bio-Techne is buying Exosome Diagnostics, which develops technology that tests for diseases with a liquid biopsy using body fluids, for $250m. The deal will see the two companies combine their expertise in blood testing to develop new diagnostics based on fluid biopsies of patients who have been diagnosed with cancer. Liquid biopsies are a less invasive alternative to surgical treatments and Exosome says its technology offers a picture of a tumour’s real-time activity as well as changes over time. It has commercialised treatments of prostate and lung cancers. The deal is expected to close in early August.
Biotechnology and diagnostic company Bio-Techne is buying Exosome Diagnostics, which develops technology that tests for diseases with a liquid biopsy using body fluids, for $250m. If the Massachusetts-based Exosome hits unspecified milestones the price could more than double. Liquid biopsies are a less invasive alternative to surgical treatments and Exosome says its technology offers a picture of a tumour’s real-time activity as well as changes over time. It has commercialised treatments of prostate and lung cancers. The deal is expected to close in early August.